

t 13 14 63 f 02 4925 1999

**e** nib@nib.com.au **w** nib.com.au



14 March 2016

The Manager Company Announcements Australia Securities Exchange Limited Level 4, Bridge Street SYDNEY NSW 2000

#### Presentation to J.P. Morgan Investment Forums – March 2016

Attached presentation delivered by nib at the J.P. Morgan Investment Forums (14 and 15 March 2016).

Yours sincerely

Michelle McPherson

Company Secretary/Chief Financial Officer




## Agenda













## Healthcare in Australia

Growth in healthcare spending driven by; wealth effect, ageing, rise of chronic disease, cost of new technology, supply induced demand and moral hazard.







\$154.6b

2014 | Australian healthcare spending (\$b) Components of healthcare spending

40% Hospitals

18% Medical services

14% Medicines


7% **Dental Services** 

5% Community health Other

16%

Australian treasury projection (Commonwealth spending)





Source: AIHW 2014 Health Expenditure Australia

## ( The role of Private Health Insurance (PHI)


What PHI does and doesn't cover		Covered	Not covered
	Public & Private Hospital (accommodation, theatre, etc), choice of specialist	<b>✓</b>	
	Medical specialist (surgeon, anaesthetist ) in hospital	<b>✓</b>	
	Medical specialist (surgeon, anaesthetist ) outside hospital		X
<b>%</b>	Pharmaceuticals in hospital	<b>✓</b>	
<b>%</b>	Pharmaceuticals outside hospital		X
<u> </u>	Diagnostics (x-ray, blood tests) in hospital	<b>✓</b>	
<u> </u>	Diagnostics (x-ray, blood tests) outside hospital		X
60	General Treatment cover (dental, optical, etc)	<b>✓</b>	
	Ambulance	<b>✓</b>	

#### Australian PHI growth drivers:

Increasing wealth and favourable economic circumstances Dissatisfaction with public system and rationing Competition and investment in marketing and growth Government "sticks and carrots"







nib



### **nib** About nib (ASX: NHF)

FY15 Group premium revenue of \$1.63b, operating profit of \$81.7m, net profit after tax of \$75.3m

More than 1,000 employees in Australia and New Zealand

Australia's 4th¹ largest private health insurer, New Zealand's 2nd largest private health insurer

Market capitalisation ~\$1.8b (439m shares on issue, 75% retail: 25% institution)

Approximately 1.3 million customers throughout Australia and New Zealand

#### **PHI** markets

Australian residents New Zealand residents International workers International students

#### Other markets<sup>2</sup>

Travel Insurance

Life Insurance

nib Options - Medical travel (launched in March 2014)

#### Recent M&A

TOWER Medical Insurance Limited acquired November 2012 for approximately \$73m (purchase price was \$81.3m, which included \$7.9m in surplus capital, which equates to approximately \$73m)

World Nomads Group acquired July 2015 for total consideration of \$95m (Australia's third largest distributor of travel insurance)

OnePath Life (NZ) policyholder book acquired December 2015 for approximately \$22.4 m.



Non-underwriting businesses



# Multi channel strategy – Continuing to expand our distribution reach


















# arhi 1H16 key performance metrics and outlook

#### Policyholder growth (cumulative policyholder growth from CY07)




#### Premium revenue



#### Underlying Operating Profit



#### Claims inflation (Rolling 12 Month Total Benefits per Person Inflation)



Above system policyholder growth for nib with focus upon under 40s and over 55s. nib has achieved above industry annual policyholder growth for over a decade.

We expect the market to continue to grow and to increase our market share and earnings.

System growth will continue for a number of reasons, including inevitable funding shift from Government to private sector.

Net growth remains highly value accretive. nib's target net margin range is 5%-5.5%.

M&A prospects remain limited but logic of industry consolidation remains compelling.

Impending Government review of PHI will be a net positive.


New distribution partnership with Qantas to launch in 2H16.





# International inbound health insurance (iihi) 1H16 key performance metrics

## Policyholder growth (cumulative policyholder growth from CY10)



#### Premium revenue



#### **Underlying Operating Profit**




nib now provides cover to almost 100,000 international students and workers (persons covered).

Gross margin and profitability expected to rebound following Saudi contract being discontinued (from 1 March 2016).











Improved result underpinned by leveraging scale and scope with 1H16 underlying operating profit result up almost 300%.

Efforts in 2H16 to focus on retention particularly in DTC channel, accelerating further digital and automation initiatives, further leveraging Group expertise and continued investment in policyholder growth (DTC, corporate/advisors and whitelabel).





## World Nomads Group (WNG) 1H16 performance metrics and outlook









World Nomads Group (WNG) underlying operating profit of \$4.2m in line with expectations, with 1H16 a 5 month result (business acquired 31 July 2015).

WNG transition and integration has gone smoothly.

Strong international growth is compensating for flat domestic market sales.

The business performed in line with expectations for the period and is on track to achieve a full year underlying operating profit result of at least \$10m.

#### World Nomads Group brands









<sup>2.</sup> Data shown for 1H16 is a 6 month result, noting WNG business acquired 31 July 2015, with 5 month result included in consolidated figures





#### Whitecoat's purpose is to help consumers:

Make more informed decisions around their health.

Choose treatment options and healthcare providers.

Connect and transact with providers.

Improve engagement with providers and share experiences with other consumers.

#### Progress to date:

200,000 patient reviews.

More than 30,000 providers registered.

Expecting 2 million visitors this year.

#### Progress to date:


Wide engagement by PHI and large provider groups (including in NZ).

Government engagement in Australia and NZ.

Expand provider registration.

Launch of Whitecoat app and increase transactions.

Provider transparency and consumer awareness of fees and out of pocket costs.







Real healthcare spending will continue to grow circa GDP  $+ 2\%^{1}$ .

Expect PHI reforms will be a net positive:

- Prosthetic pricing
- Risk equalisation
- Primary care and MBS Review
- New funding devices (e.g. health savings accounts)
- Hospital contracting

Claims inflation may be taking a lower trajectory with opportunities to improve PHI affordability and stabilise margins.

Adjacent businesses will increase contribution to earnings including significant improvement in international (inbound) business from FY17.

Some building pressures on PHI industry consolidation.

Whitecoat digital platform will help reduce over servicing/cost variation and generally improve consumer sovereignty.




	Total Health Expenditure	GDP
	Average annual growth rate (%)	Growth rate (%)
2003-04 to 2008-09	5.78	3.08
2008-09 to 2013-14	4.23	2.60
2003-04 to 2013-14	5.00	2.84





(\$m)	FY16 (GUIDANCE)
Statutory operating profit	90–100
One-off transaction and M&A costs	4–5
One-off transaction and M&A costs (WNG)	3.5-4.51
One-off transaction and M&A costs (OnePath NZ)	0.3
Amortisation of acquired intangibles	8–9
Amortisation of acquired intangibles (IMAN)	1
Amortisation of acquired intangibles (nib NZ)	3
Amortisation of acquired intangibles (WNG)	3–4
Amortisation of acquired intangibles (OnePath NZ)	1
Underlying operating profit	102–114



FY16 investment income forecast to be lower than FY15 in light of a lower return environment and a reduced capital base (as a result of capital management initiatives) and M&A. FY16 investment returns to be in line with relevant internal benchmarks<sup>2</sup>.

Some building pressures on PHI industry consolidation.

Ordinary dividend payout ratio 60%-70% of full year NPAT.

- 1. Includes accrual of potential retention bonuses associated with WNG acquisition subject to satisfying service period.
- 2. Internal Investment benchmarks
  - $Australian \ Regulatory \ capital \ (75\%/25\% \ defensive/growth) target \ for \ portfolio \ bank \ bill \ index \ plus \ 1\%.$
  - New Zealand regulatory capital (100% defensive) (1) For core portfolio target is a 6 month bank bill index (2) For premium payback portfolio target is a 3.0 years interest rate swap index
  - Surplus capital (100% defensive) bank bill index

